利培酮治疗儿童期首发精神分裂症70例临床分析  

Clinical Analgsis of Risperidone in the Treatment of 70 Childhood Patients with First-episode Schizophrenia.

作　　者：曹红军[1] 尤海峰 范凤兰 张静 

机构地区：[1]中国.河南省驻马店市精神病医院,463000

出　　处：《健康心理学杂志》2003年第5期331-332,共2页Health Psychology Journal

摘　　要：目的　了解利培酮治疗儿童期首发精神分裂症患者的疗效和安全性。方法　对 70例年龄 <1 4岁首次发病患儿用利培酮治疗 6周 ,以阳性和阴性症状量表 ( PANSS)和简明精神病评定量表 ( BPRS)评定临床疗效。以副反应量表 ( TESS)和实验室监测评价安全性 ,于基线时 ,实验第 1、2、4、6周末分别评定各量表。统计方法为描述性分析和配对 t检验。结果　共收集有效病例 70例 ,其中基本痊愈 3 4.3 % ( 2 4/ 70 ) ,显著进步 45 .7% ( 3 2 / 70 ) ,好转 1 0 % ( 7/ 70 )和无效 1 0 % ( 7/ 70 )。 BPRS总分、PANSS总分、PANSS各分量表分治疗前后比较均有显著性差异 ( P<0 .0 1 ) ,利培酮对阳性、阴性症状以及一般精神病性症状均有良好疗效。副反应主要为锥体外系反应。结论　对儿童期首发精神分裂症 ,利培酮疗效较好 。Objective To study efficacy and safety of risperidone in the treatment of childhood patients with first episode schizophrehia.Methods 70 patients with first episode schizophrenia(age<14 years)were included in this 6 week open clinical study.The positive and Negative syndrome scale(PANSS) and brief psychiatric Rating scale(BPRS) derived from the PANSS were used to assess the clinical efficacy.The Treatment emergent side effect scale (TESS) and laboratory tests were used to assess the adverse effects.Scales were evaluated at baseline and the end of 1、2、4、6.Descriptive analsysis and paired t test were performed in statistical analysis.Results 70 valid cases were collected,among the 70 patients,34.3% met the criteria of complete relief,45.7% significantly improved,10% improved,and 10% got no change.There were significant differences existed in total BPRS scores,total PANSS scores and factor scores of PANSS after 6 week treatment of risperidone.Risperidone showed good effect on the positive,negative as well as general psychopathological symptoms of childhood patients with first episode schizophrenia.The main side effect was slight EPS.Conclusion This study suggests that risperidone is an effective and safe antipsychotic in the treatment of childhood patients with first episode schizophrenia.

关 键 词：利培酮 儿童期 首发精神分裂症 药物治疗 疗效 安全性 

分 类 号：R749.3[医药卫生—神经病学与精神病学]